Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522096 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ATMALDH1A1HPGD | |
| SCHEMBL18497643 | 0.85 | ATM (0.44) | HSD17B10SMN1; SMN2ATMALDH1A1PDE8B | |
| SCHEMBL18497645 | 0.85 | ATM (0.44) | HSD17B10SMN1; SMN2ATMALDH1A1PDE8B | |
| SCHEMBL34473181 | 0.85 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ATMALDH1A1HPGD | |
| SCHEMBL190268 | 0.85 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2ATMALDH1A1PDE8B | |
| SCHEMBL31509972 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2ATMALDH1A1HPGD | |
| SCHEMBL1598305 | 0.84 | CYP2D6 (0.44) | HSD17B10SMN1; SMN2ATMALDH1A1PDE8B | |
| SCHEMBL1598307 | 0.84 | CYP2D6 (0.44) | HSD17B10SMN1; SMN2ATMALDH1A1PDE8B | |
| SCHEMBL29778252 | 0.83 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2ATMHPGDEPHX1 | |
| SCHEMBL20182480 | 0.83 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2ATMALDH1A1PDE8B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| CN-110475777-B | Novel pyrido [2,3-b ] indole compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3601282-A1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-20180327425-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2018178041-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-04 | — | — | WO | disclosed |
| EP-1100824-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2011-03-02 | — | — | EP | disclosed |
| EP-1100824-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2011-03-02 | — | — | EP | disclosed |
| US-7576062-B2 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | NOVO NORDISK A/S (DK) | 2009-08-18 | — | — | US | disclosed |
| US-7576062-B2 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | NOVO NORDISK A/S (DK) | 2009-08-18 | — | — | US | disclosed |
| US-7576062-B2 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | NOVO NORDISK A/S (DK) | 2009-08-18 | — | — | US | disclosed |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | HELSINN HEALTHCARE SA (CH) | 2005-10-20 | — | — | US | disclosed |
| US-6919315-B1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-07-19 | — | — | US | disclosed |
| EP-1100824-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001726-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327425-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | HSD17B10 2741/4885SMN1; SMN2 4094/4885ATM 3884/4885 |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | HSD17B10 2741/4885SMN1; SMN2 4094/4885ATM 3884/4885 |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, KYNU | HSD17B10 2701/4885SMN1; SMN2 3572/4885ATM 4029/4885 |
| US-20050233981-A1 | Administering a patient an effective amount of (2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide; treat the medical disorders resulting from a deficiency in growth hormone | GHSR, GHRHR, MC2R | HSD17B10 573/4885SMN1; SMN2 896/4885ATM 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.